Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

Similar articles for PubMed (Select 23908395)

1.

Preclinical safety assessment of a recombinant plague vaccine (rF1V).

Price JL, Manetz TS, Shearer JD, House RV.

Int J Toxicol. 2013 Sep-Oct;32(5):327-35. doi: 10.1177/1091581813497405. Epub 2013 Aug 1.

PMID:
23908395
2.

Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B).

Shearer JD, Manetz TS, House RV.

Vaccine. 2012 Mar 2;30(11):1917-26. doi: 10.1016/j.vaccine.2012.01.035. Epub 2012 Jan 23.

PMID:
22269871
3.

Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine.

Huang J, D'Souza AJ, Alarcon JB, Mikszta JA, Ford BM, Ferriter MS, Evans M, Stewart T, Amemiya K, Ulrich RG, Sullivan VJ.

Clin Vaccine Immunol. 2009 May;16(5):719-25. doi: 10.1128/CVI.00447-08. Epub 2009 Mar 4.

4.

Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.

Williamson ED, Packer PJ, Waters EL, Simpson AJ, Dyer D, Hartings J, Twenhafel N, Pitt ML.

Vaccine. 2011 Jun 24;29(29-30):4771-7. doi: 10.1016/j.vaccine.2011.04.084. Epub 2011 May 12.

PMID:
21570437
5.

Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.

Jones T, Adamovicz JJ, Cyr SL, Bolt CR, Bellerose N, Pitt LM, Lowell GH, Burt DS.

Vaccine. 2006 Mar 6;24(10):1625-32. Epub 2005 Oct 7.

PMID:
16243411
6.

Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.

Albrecht MT, Eyles JE, Baillie LW, Keane-Myers AM.

FEMS Immunol Med Microbiol. 2012 Aug;65(3):505-9. doi: 10.1111/j.1574-695X.2012.00974.x. Epub 2012 May 21.

7.

Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts.

Arlen PA, Singleton M, Adamovicz JJ, Ding Y, Davoodi-Semiromi A, Daniell H.

Infect Immun. 2008 Aug;76(8):3640-50. doi: 10.1128/IAI.00050-08. Epub 2008 May 27.

8.

Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V).

Fellows P, Adamovicz J, Hartings J, Sherwood R, Mega W, Brasel T, Barr E, Holland L, Lin W, Rom A, Blackwelder W, Price J, Morris S, Snow D, Hart MK.

Vaccine. 2010 Nov 16;28(49):7748-56. doi: 10.1016/j.vaccine.2010.09.062. Epub 2010 Oct 15.

PMID:
20920572
9.

A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.

Yamanaka H, Hoyt T, Yang X, Golden S, Bosio CM, Crist K, Becker T, Maddaloni M, Pascual DW.

Infect Immun. 2008 Oct;76(10):4564-73. doi: 10.1128/IAI.00581-08. Epub 2008 Aug 11.

10.

A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague.

Chichester JA, Musiychuk K, Farrance CE, Mett V, Lyons J, Mett V, Yusibov V.

Vaccine. 2009 May 26;27(25-26):3471-4. doi: 10.1016/j.vaccine.2009.01.050. Epub 2009 Feb 5.

PMID:
19200825
11.

Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.

Thomas RJ, Webber D, Collinge A, Stagg AJ, Bailey SC, Nunez A, Gates A, Jayasekera PN, Taylor RR, Eley S, Titball RW.

Infect Immun. 2009 Apr;77(4):1315-23. doi: 10.1128/IAI.01473-08. Epub 2009 Feb 2.

12.

Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270.

Qi Z, Zhou L, Zhang Q, Ren L, Dai R, Wu B, Wang T, Zhu Z, Yang Y, Cui B, Wang Z, Wang H, Qiu Y, Guo Z, Yang R, Wang X.

Vaccine. 2010 Feb 10;28(6):1655-60. doi: 10.1016/j.vaccine.2009.02.078. Epub 2009 Mar 9.

PMID:
20079562
13.

A new improved sub-unit vaccine for plague: the basis of protection.

Williamson ED, Eley SM, Griffin KF, Green M, Russell P, Leary SE, Oyston PC, Easterbrook T, Reddin KM, Robinson A, et al.

FEMS Immunol Med Microbiol. 1995 Dec;12(3-4):223-30.

PMID:
8745007
14.

Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.

Powell BS, Andrews GP, Enama JT, Jendrek S, Bolt C, Worsham P, Pullen JK, Ribot W, Hines H, Smith L, Heath DG, Adamovicz JJ.

Biotechnol Prog. 2005 Sep-Oct;21(5):1490-510.

PMID:
16209555
15.

Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.

Goodin JL, Nellis DF, Powell BS, Vyas VV, Enama JT, Wang LC, Clark PK, Giardina SL, Adamovicz JJ, Michiel DF.

Protein Expr Purif. 2007 May;53(1):63-79. Epub 2006 Dec 31.

16.

Plague vaccines and the molecular basis of immunity against Yersinia pestis.

Quenee LE, Schneewind O.

Hum Vaccin. 2009 Dec;5(12):817-23. Epub 2009 Dec 1. Review.

PMID:
19786842
17.
18.

CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.

Amemiya K, Meyers JL, Rogers TE, Fast RL, Bassett AD, Worsham PL, Powell BS, Norris SL, Krieg AM, Adamovicz JJ.

Vaccine. 2009 Apr 6;27(16):2220-9. doi: 10.1016/j.vaccine.2009.02.016. Epub 2009 Feb 13.

PMID:
19428836
19.

Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.

Gupta G, Khan AA, Rao DN.

Scand J Immunol. 2010 Mar;71(3):186-98. doi: 10.1111/j.1365-3083.2009.02365.x.

PMID:
20415784
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk